PBT2 and zinc work together to fight antibiotic resistance, page-79

Skint, DI published the news on the 14th of Dec, not in Nov. The paper it self was first published on 11th of Dec and was accepted in 5 days on 5th of Nov. 

PBT2 was a hit compound in the study by Bohlmann et al but not any more for Prana, everybody in Prana talked only about PBT434. This is why they in Prana were not so keen what some other were studying (???) with their PBT2 and with bacteria. Think bacteria, not anything for Prana !!! Nothing was expected about this study. It is easier to think that Viagra is a drug for high blood pressure than that an Alzheimer's drug kills bacteria resistent to all other drugs and these bacteria are killing millions in few years !!!. The value of this invention is billions just in my opinion .
It is easy to understand that Prana did not expect anything about this co-operation. The result was surprise to Bohlmann et al, to us investors and a very big surprise to Prana. I am sure these results were not understood when the Sinclair deal was done, but I do not know this. 
If Prana management had known the results the co-operation agreement would be on totally different level and it is clear that also Sinclair understands this. They are also very happy when they bought 10 % of the company from the market.